Plain-English translation of NCT04901273 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing Homologous PRP—a treatment made from blood platelets—as an injection directly into the knee joint to help relieve osteoarthritis pain and inflammation. About 200 people over age 65 with knee arthritis will receive either the medication or a salt-water placebo injection. Researchers will track how well each treatment works over 6 to 12 months using clinical exams and special thermal imaging to measure inflammation.
Knee arthritis is common in older adults and causes pain that limits daily activities. This medication may help reduce inflammation and cartilage damage, offering a gentler alternative to surgery for people who haven't found relief with other treatments.
You likely qualify if…
You likely don't qualify if…
You'll receive one injection into your knee—either the active treatment or a placebo. You won't know which one at first. Then you'll visit the clinic at 1, 3, and 6 months for check-ups and thermal imaging scans of your knee to measure inflammation. If you're in the placebo group, you can switch to the active treatment after 6 months and continue follow-up visits. The total study lasts 6 to 12 months depending on which group you're in.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Italy
Istituto Ortopedico Rizzoli
Enrollment target
~204 participants
Started
December 2021
Primary completion
December 2028
Age range
65 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Roberta Licciardi, Msc
Istituto Ortopedico Rizzoli
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.